Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACELYRIN, INC. (SLRN)
:SLRN
Holding SLRN?
Track your performance easily
SLRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.91 - $8.89
Previous CloseN/A
Volume2.42M
Average Volume (3M)1.41M
Market Cap
$199.65M
Enterprise Value-$63.63M
Total Cash (Recent Filing)$721.33M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 27, 2025EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding100,325,570
10 Day Avg. Volume2,635,546
30 Day Avg. Volume1,414,001
Standard Deviation0.24
R-Squared0.10
Alpha-0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.20
Forecast
1Y Price Target
$9.40Price Target Upside372.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
ACELYRIN, INC. News
PremiumCompany Announcements
ACELYRIN Faces CFO Resignation and Trial SetbackBulls Say, Bears Say
Bulls Say
Market StrategyThe company will focus future capital investments primarily for developing loni in TED, indicating a strategic emphasis on a promising treatment area.
Regulatory ProgressThe company recently completed an end of Phase 2 meeting with the FDA and obtained agreement on Phase 3 size, endpoints, and dosing schedule for lonigutamab for treatment of thyroid eye disease, viewed as a positive update.
Safety ProfileLoni's safety profile looks promising versus competitors, with no hearing impairment or hyperglycemia events reported, potentially due to its non-competitive binding mechanism.
Bears Say
Clinical Trial ConcernsThe Phase 2b/3 study of izokibep for treatment of uveitis did not meet the primary endpoint of time to treatment failure vs placebo.
Financial PerformanceFollowing the removal of uveitis from the SLRN model, the base case peak sales projection decreases from ~$550M to ~$500M.
Management ChangesCFO and CBO Gil Labrucherie will transition from Acelyrin in early 2025.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SLRN FAQ
What was ACELYRIN, INC.’s price range in the past 12 months?
ACELYRIN, INC. lowest stock price was $1.91 and its highest was $8.88 in the past 12 months.
What is ACELYRIN, INC.’s market cap?
ACELYRIN, INC.’s market cap is $199.65M.
When is ACELYRIN, INC.’s upcoming earnings report date?
ACELYRIN, INC.’s upcoming earnings report date is Mar 27, 2025 which is in 65 days.
How were ACELYRIN, INC.’s earnings last quarter?
ACELYRIN, INC. released its earnings results on Nov 13, 2024. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.309.
Is ACELYRIN, INC. overvalued?
According to Wall Street analysts ACELYRIN, INC.’s price is currently Undervalued.
Does ACELYRIN, INC. pay dividends?
ACELYRIN, INC. does not currently pay dividends.
What is ACELYRIN, INC.’s EPS estimate?
ACELYRIN, INC.’s EPS estimate is -0.8.
How many shares outstanding does ACELYRIN, INC. have?
ACELYRIN, INC. has 100,325,570 shares outstanding.
What happened to ACELYRIN, INC.’s price movement after its last earnings report?
ACELYRIN, INC. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -13.712%.
Which hedge fund is a major shareholder of ACELYRIN, INC.?
Among the largest hedge funds holding ACELYRIN, INC.’s share is Woodline Partners LP. It holds ACELYRIN, INC.’s shares valued at 2M.
---
ACELYRIN, INC. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.40 (372.36% Upside)
$9.40 (372.36% Upside)
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 12.5%
Last 30 Days ▲ 12.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.85%
12-Months-Change
Fundamentals
Return on Equity
-41.95%
Trailing 12-Months
Asset Growth
-22.76%
Trailing 12-Months
Company Description
ACELYRIN, INC.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
---
SLRN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant progress in pipeline prioritization and financial management, offset by challenges in clinical development decisions and safety considerations.Read More>---
SLRN Stock 12 Month Forecast
Average Price Target
$9.40
▲(372.36% Upside)
Technical Analysis
Ardelyx
―
Blueprint Medicines
―
Crinetics Pharmaceuticals
―
Fate Therapeutics
―
Prothena
―
Best Analysts Covering SLRN
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-55.50%
assigned a buy rating 15 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -55.50% per trade.
---